Allergy Asthma Clin Immunol:牛磺酸通过调节IL-35/STAT1途径促进过敏性鼻炎模型中CD4 + CD25 + FOXP3 + Treg细胞的产生

2021-06-27 AlexYang MedSci原创

过敏性鼻炎(AR)是全世界最普遍的免疫性疾病之一。然而,常见的治疗方法往往有很大的副作用,或者对大多数人来说费用过高。大量的治疗方法已用于治疗AR,包括抗组胺药、类固醇和免疫调节剂。在这些治疗方法中,

过敏性鼻炎(AR)是全世界最普遍的免疫性疾病之一。然而,常见的治疗方法往往有很大的副作用,或者对大多数人来说费用过高。大量的治疗方法已用于治疗AR,包括抗组胺药、类固醇和免疫调节剂。在这些治疗方法中,条件必需氨基酸牛磺酸在治疗AR方面显示出潜在的疗效,且副作用最小,但仍进行充分研究。牛磺酸先前已证明可减少AR症状。

近期,有研究人员调查了牛磺酸在调节T调控细胞、AR中的细胞因子反应和健康鼻粘膜恢复中的作用

研究人员比较了20名健康捐赠者和20名AR患者的血液样本,在有无牛磺酸处理或IL-35中和的情况下,比较了CD4+CD25+FoxP3+T调节(Treg)细胞群百分比、细胞因子释放和STAT1信号。对OVA诱导的AR小鼠模型进行溶质、牛磺酸或牛磺酸加IL-35中和抗体处理,并对打喷嚏频率、炎症细胞因子反应、鼻粘膜小球细胞密度和T调节细胞百分比进行了检测。并进一步检查了CD4+细胞的细胞因子释放、STAT1磷酸化,以及对有无STAT1抑制剂的抗IL-35抗体的反应。

结果发现,正常献血者和AR患者的血液分析发现,AR患者的CD4+CD25+FoxP3+Treg细胞减少,Treg百分比和IL-35释放之间有很强的关联性。与正常对照小鼠相比,在未经处理的AR小鼠中也发现了类似的Treg抑制模式,其中Treg百分比减少,IL-35释放也相应减少。另外,AR小鼠还表现出打喷嚏的频率增加,鼻粘膜上的绒毛细胞浸润,以及CD4+细胞的IL-35释放减少。相反,在AR模型小鼠中,CD4+细胞分泌的IL-4、IL-5和IL-13有所增加,STAT1的磷酸化也有所增加。当用牛磺酸治疗AR模型小鼠时,打喷嚏的频率和鼻粘膜细胞杯状细胞的含量减少,而Treg的丰度则增加到正常小鼠的水平。相应地,IL-35的释放得到恢复,而CD4+细胞分泌的IL-4、IL-5和IL-13受到抑制。同样,牛磺酸处理也抑制了STAT1的磷酸化。同时进行牛磺酸和IL-35中和抗体处理的则表现出AR病理学,包括频繁打喷嚏和高杯状细胞含量,而保留了Tregs的恢复。此外,暴露于重组IL-35的小鼠AR模型CD4+细胞的反应为炎症细胞因子释放的减少和STAT1磷酸化的降低,与牛磺酸处理的效果相似。

AR患者血液中IL-35与CD4+CD25+Foxp3+ Treg细胞比例正相关

综上所述,牛磺酸能够诱导AR中IL-35的释放;IL-35通过STAT1依赖的途径促进CD4+CD25+FoxP3+Treg细胞的产生。牛磺酸恢复Treg细胞群可使炎症反应正常化,减少AR症状,并减少AR的组织病理体征

原始出处:

Jing Zhou , Yi Lu , Wei Wu et al. Taurine promotes the production of CD4 + CD25 +FOXP3 + Treg cells through regulating IL-35/STAT1 pathway in a mouse allergic rhinitis model. Allergy Asthma Clin Immunol. Jun 2021

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1864295, encodeId=b52a186429550, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Fri Jul 23 05:58:44 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782732, encodeId=2b9e1e827322e, content=<a href='/topic/show?id=9661429858' target=_blank style='color:#2F92EE;'>#CD25#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4298, encryptionId=9661429858, topicName=CD25)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Nov 07 16:58:44 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977176, encodeId=2aab19e7176aa, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Apr 30 10:58:44 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653787, encodeId=9ed01653e877e, content=<a href='/topic/show?id=8d02e630a6' target=_blank style='color:#2F92EE;'>#FOXP3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7630, encryptionId=8d02e630a6, topicName=FOXP3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be7924361871, createdName=zhs3890, createdTime=Mon Mar 14 15:58:44 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047423, encodeId=3d31204e42362, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon May 16 01:58:44 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712845, encodeId=b6c31e128455b, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Dec 28 00:58:44 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036922, encodeId=baf12036922e2, content=<a href='/topic/show?id=d27d966619' target=_blank style='color:#2F92EE;'>#IL-35#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9666, encryptionId=d27d966619, topicName=IL-35)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Sun May 22 05:58:44 CST 2022, time=2022-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329519, encodeId=0b9a13295192a, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343530, encodeId=e56b134353092, content=<a href='/topic/show?id=7dd51e788b8' target=_blank style='color:#2F92EE;'>#Treg细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17788, encryptionId=7dd51e788b8, topicName=Treg细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3ad2500191, createdName=12498dd9m11暂无昵称, createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477218, encodeId=6cb214e7218ed, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=)]
    2021-07-23 qidongfanjian
  2. [GetPortalCommentsPageByObjectIdResponse(id=1864295, encodeId=b52a186429550, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Fri Jul 23 05:58:44 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782732, encodeId=2b9e1e827322e, content=<a href='/topic/show?id=9661429858' target=_blank style='color:#2F92EE;'>#CD25#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4298, encryptionId=9661429858, topicName=CD25)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Nov 07 16:58:44 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977176, encodeId=2aab19e7176aa, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Apr 30 10:58:44 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653787, encodeId=9ed01653e877e, content=<a href='/topic/show?id=8d02e630a6' target=_blank style='color:#2F92EE;'>#FOXP3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7630, encryptionId=8d02e630a6, topicName=FOXP3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be7924361871, createdName=zhs3890, createdTime=Mon Mar 14 15:58:44 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047423, encodeId=3d31204e42362, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon May 16 01:58:44 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712845, encodeId=b6c31e128455b, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Dec 28 00:58:44 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036922, encodeId=baf12036922e2, content=<a href='/topic/show?id=d27d966619' target=_blank style='color:#2F92EE;'>#IL-35#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9666, encryptionId=d27d966619, topicName=IL-35)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Sun May 22 05:58:44 CST 2022, time=2022-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329519, encodeId=0b9a13295192a, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343530, encodeId=e56b134353092, content=<a href='/topic/show?id=7dd51e788b8' target=_blank style='color:#2F92EE;'>#Treg细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17788, encryptionId=7dd51e788b8, topicName=Treg细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3ad2500191, createdName=12498dd9m11暂无昵称, createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477218, encodeId=6cb214e7218ed, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=)]
    2021-11-07 陈吴1234
  3. [GetPortalCommentsPageByObjectIdResponse(id=1864295, encodeId=b52a186429550, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Fri Jul 23 05:58:44 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782732, encodeId=2b9e1e827322e, content=<a href='/topic/show?id=9661429858' target=_blank style='color:#2F92EE;'>#CD25#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4298, encryptionId=9661429858, topicName=CD25)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Nov 07 16:58:44 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977176, encodeId=2aab19e7176aa, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Apr 30 10:58:44 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653787, encodeId=9ed01653e877e, content=<a href='/topic/show?id=8d02e630a6' target=_blank style='color:#2F92EE;'>#FOXP3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7630, encryptionId=8d02e630a6, topicName=FOXP3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be7924361871, createdName=zhs3890, createdTime=Mon Mar 14 15:58:44 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047423, encodeId=3d31204e42362, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon May 16 01:58:44 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712845, encodeId=b6c31e128455b, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Dec 28 00:58:44 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036922, encodeId=baf12036922e2, content=<a href='/topic/show?id=d27d966619' target=_blank style='color:#2F92EE;'>#IL-35#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9666, encryptionId=d27d966619, topicName=IL-35)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Sun May 22 05:58:44 CST 2022, time=2022-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329519, encodeId=0b9a13295192a, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343530, encodeId=e56b134353092, content=<a href='/topic/show?id=7dd51e788b8' target=_blank style='color:#2F92EE;'>#Treg细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17788, encryptionId=7dd51e788b8, topicName=Treg细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3ad2500191, createdName=12498dd9m11暂无昵称, createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477218, encodeId=6cb214e7218ed, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=)]
    2022-04-30 skhzy
  4. [GetPortalCommentsPageByObjectIdResponse(id=1864295, encodeId=b52a186429550, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Fri Jul 23 05:58:44 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782732, encodeId=2b9e1e827322e, content=<a href='/topic/show?id=9661429858' target=_blank style='color:#2F92EE;'>#CD25#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4298, encryptionId=9661429858, topicName=CD25)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Nov 07 16:58:44 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977176, encodeId=2aab19e7176aa, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Apr 30 10:58:44 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653787, encodeId=9ed01653e877e, content=<a href='/topic/show?id=8d02e630a6' target=_blank style='color:#2F92EE;'>#FOXP3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7630, encryptionId=8d02e630a6, topicName=FOXP3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be7924361871, createdName=zhs3890, createdTime=Mon Mar 14 15:58:44 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047423, encodeId=3d31204e42362, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon May 16 01:58:44 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712845, encodeId=b6c31e128455b, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Dec 28 00:58:44 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036922, encodeId=baf12036922e2, content=<a href='/topic/show?id=d27d966619' target=_blank style='color:#2F92EE;'>#IL-35#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9666, encryptionId=d27d966619, topicName=IL-35)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Sun May 22 05:58:44 CST 2022, time=2022-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329519, encodeId=0b9a13295192a, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343530, encodeId=e56b134353092, content=<a href='/topic/show?id=7dd51e788b8' target=_blank style='color:#2F92EE;'>#Treg细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17788, encryptionId=7dd51e788b8, topicName=Treg细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3ad2500191, createdName=12498dd9m11暂无昵称, createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477218, encodeId=6cb214e7218ed, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=)]
    2022-03-14 zhs3890
  5. [GetPortalCommentsPageByObjectIdResponse(id=1864295, encodeId=b52a186429550, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Fri Jul 23 05:58:44 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782732, encodeId=2b9e1e827322e, content=<a href='/topic/show?id=9661429858' target=_blank style='color:#2F92EE;'>#CD25#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4298, encryptionId=9661429858, topicName=CD25)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Nov 07 16:58:44 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977176, encodeId=2aab19e7176aa, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Apr 30 10:58:44 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653787, encodeId=9ed01653e877e, content=<a href='/topic/show?id=8d02e630a6' target=_blank style='color:#2F92EE;'>#FOXP3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7630, encryptionId=8d02e630a6, topicName=FOXP3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be7924361871, createdName=zhs3890, createdTime=Mon Mar 14 15:58:44 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047423, encodeId=3d31204e42362, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon May 16 01:58:44 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712845, encodeId=b6c31e128455b, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Dec 28 00:58:44 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036922, encodeId=baf12036922e2, content=<a href='/topic/show?id=d27d966619' target=_blank style='color:#2F92EE;'>#IL-35#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9666, encryptionId=d27d966619, topicName=IL-35)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Sun May 22 05:58:44 CST 2022, time=2022-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329519, encodeId=0b9a13295192a, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343530, encodeId=e56b134353092, content=<a href='/topic/show?id=7dd51e788b8' target=_blank style='color:#2F92EE;'>#Treg细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17788, encryptionId=7dd51e788b8, topicName=Treg细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3ad2500191, createdName=12498dd9m11暂无昵称, createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477218, encodeId=6cb214e7218ed, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1864295, encodeId=b52a186429550, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Fri Jul 23 05:58:44 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782732, encodeId=2b9e1e827322e, content=<a href='/topic/show?id=9661429858' target=_blank style='color:#2F92EE;'>#CD25#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4298, encryptionId=9661429858, topicName=CD25)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Nov 07 16:58:44 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977176, encodeId=2aab19e7176aa, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Apr 30 10:58:44 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653787, encodeId=9ed01653e877e, content=<a href='/topic/show?id=8d02e630a6' target=_blank style='color:#2F92EE;'>#FOXP3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7630, encryptionId=8d02e630a6, topicName=FOXP3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be7924361871, createdName=zhs3890, createdTime=Mon Mar 14 15:58:44 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047423, encodeId=3d31204e42362, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon May 16 01:58:44 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712845, encodeId=b6c31e128455b, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Dec 28 00:58:44 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036922, encodeId=baf12036922e2, content=<a href='/topic/show?id=d27d966619' target=_blank style='color:#2F92EE;'>#IL-35#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9666, encryptionId=d27d966619, topicName=IL-35)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Sun May 22 05:58:44 CST 2022, time=2022-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329519, encodeId=0b9a13295192a, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343530, encodeId=e56b134353092, content=<a href='/topic/show?id=7dd51e788b8' target=_blank style='color:#2F92EE;'>#Treg细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17788, encryptionId=7dd51e788b8, topicName=Treg细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3ad2500191, createdName=12498dd9m11暂无昵称, createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477218, encodeId=6cb214e7218ed, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1864295, encodeId=b52a186429550, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Fri Jul 23 05:58:44 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782732, encodeId=2b9e1e827322e, content=<a href='/topic/show?id=9661429858' target=_blank style='color:#2F92EE;'>#CD25#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4298, encryptionId=9661429858, topicName=CD25)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Nov 07 16:58:44 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977176, encodeId=2aab19e7176aa, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Apr 30 10:58:44 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653787, encodeId=9ed01653e877e, content=<a href='/topic/show?id=8d02e630a6' target=_blank style='color:#2F92EE;'>#FOXP3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7630, encryptionId=8d02e630a6, topicName=FOXP3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be7924361871, createdName=zhs3890, createdTime=Mon Mar 14 15:58:44 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047423, encodeId=3d31204e42362, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon May 16 01:58:44 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712845, encodeId=b6c31e128455b, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Dec 28 00:58:44 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036922, encodeId=baf12036922e2, content=<a href='/topic/show?id=d27d966619' target=_blank style='color:#2F92EE;'>#IL-35#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9666, encryptionId=d27d966619, topicName=IL-35)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Sun May 22 05:58:44 CST 2022, time=2022-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329519, encodeId=0b9a13295192a, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343530, encodeId=e56b134353092, content=<a href='/topic/show?id=7dd51e788b8' target=_blank style='color:#2F92EE;'>#Treg细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17788, encryptionId=7dd51e788b8, topicName=Treg细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3ad2500191, createdName=12498dd9m11暂无昵称, createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477218, encodeId=6cb214e7218ed, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=)]
    2022-05-22 qblt
  8. [GetPortalCommentsPageByObjectIdResponse(id=1864295, encodeId=b52a186429550, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Fri Jul 23 05:58:44 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782732, encodeId=2b9e1e827322e, content=<a href='/topic/show?id=9661429858' target=_blank style='color:#2F92EE;'>#CD25#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4298, encryptionId=9661429858, topicName=CD25)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Nov 07 16:58:44 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977176, encodeId=2aab19e7176aa, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Apr 30 10:58:44 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653787, encodeId=9ed01653e877e, content=<a href='/topic/show?id=8d02e630a6' target=_blank style='color:#2F92EE;'>#FOXP3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7630, encryptionId=8d02e630a6, topicName=FOXP3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be7924361871, createdName=zhs3890, createdTime=Mon Mar 14 15:58:44 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047423, encodeId=3d31204e42362, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon May 16 01:58:44 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712845, encodeId=b6c31e128455b, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Dec 28 00:58:44 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036922, encodeId=baf12036922e2, content=<a href='/topic/show?id=d27d966619' target=_blank style='color:#2F92EE;'>#IL-35#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9666, encryptionId=d27d966619, topicName=IL-35)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Sun May 22 05:58:44 CST 2022, time=2022-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329519, encodeId=0b9a13295192a, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343530, encodeId=e56b134353092, content=<a href='/topic/show?id=7dd51e788b8' target=_blank style='color:#2F92EE;'>#Treg细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17788, encryptionId=7dd51e788b8, topicName=Treg细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3ad2500191, createdName=12498dd9m11暂无昵称, createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477218, encodeId=6cb214e7218ed, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=)]
    2021-06-29 膀胱癌
  9. [GetPortalCommentsPageByObjectIdResponse(id=1864295, encodeId=b52a186429550, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Fri Jul 23 05:58:44 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782732, encodeId=2b9e1e827322e, content=<a href='/topic/show?id=9661429858' target=_blank style='color:#2F92EE;'>#CD25#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4298, encryptionId=9661429858, topicName=CD25)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Nov 07 16:58:44 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977176, encodeId=2aab19e7176aa, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Apr 30 10:58:44 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653787, encodeId=9ed01653e877e, content=<a href='/topic/show?id=8d02e630a6' target=_blank style='color:#2F92EE;'>#FOXP3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7630, encryptionId=8d02e630a6, topicName=FOXP3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be7924361871, createdName=zhs3890, createdTime=Mon Mar 14 15:58:44 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047423, encodeId=3d31204e42362, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon May 16 01:58:44 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712845, encodeId=b6c31e128455b, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Dec 28 00:58:44 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036922, encodeId=baf12036922e2, content=<a href='/topic/show?id=d27d966619' target=_blank style='color:#2F92EE;'>#IL-35#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9666, encryptionId=d27d966619, topicName=IL-35)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Sun May 22 05:58:44 CST 2022, time=2022-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329519, encodeId=0b9a13295192a, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343530, encodeId=e56b134353092, content=<a href='/topic/show?id=7dd51e788b8' target=_blank style='color:#2F92EE;'>#Treg细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17788, encryptionId=7dd51e788b8, topicName=Treg细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3ad2500191, createdName=12498dd9m11暂无昵称, createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477218, encodeId=6cb214e7218ed, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1864295, encodeId=b52a186429550, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Fri Jul 23 05:58:44 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782732, encodeId=2b9e1e827322e, content=<a href='/topic/show?id=9661429858' target=_blank style='color:#2F92EE;'>#CD25#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4298, encryptionId=9661429858, topicName=CD25)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Nov 07 16:58:44 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977176, encodeId=2aab19e7176aa, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sat Apr 30 10:58:44 CST 2022, time=2022-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653787, encodeId=9ed01653e877e, content=<a href='/topic/show?id=8d02e630a6' target=_blank style='color:#2F92EE;'>#FOXP3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7630, encryptionId=8d02e630a6, topicName=FOXP3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be7924361871, createdName=zhs3890, createdTime=Mon Mar 14 15:58:44 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047423, encodeId=3d31204e42362, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon May 16 01:58:44 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1712845, encodeId=b6c31e128455b, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Dec 28 00:58:44 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036922, encodeId=baf12036922e2, content=<a href='/topic/show?id=d27d966619' target=_blank style='color:#2F92EE;'>#IL-35#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9666, encryptionId=d27d966619, topicName=IL-35)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Sun May 22 05:58:44 CST 2022, time=2022-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329519, encodeId=0b9a13295192a, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1343530, encodeId=e56b134353092, content=<a href='/topic/show?id=7dd51e788b8' target=_blank style='color:#2F92EE;'>#Treg细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17788, encryptionId=7dd51e788b8, topicName=Treg细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3ad2500191, createdName=12498dd9m11暂无昵称, createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477218, encodeId=6cb214e7218ed, content=<a href='/topic/show?id=81f91e786ce' target=_blank style='color:#2F92EE;'>#Treg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17786, encryptionId=81f91e786ce, topicName=Treg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96827361646, createdName=12498484m48(暂无昵称), createdTime=Tue Jun 29 11:58:44 CST 2021, time=2021-06-29, status=1, ipAttribution=)]

相关资讯

梅斯呼吸疾病进展(004期)

往期参见:梅斯呼吸疾病进展(第003期)

Allergy Asthma Clin Immunol:暴露于黑碳和花粉过敏原的鼻腔上皮细胞的转录组变化

空气污染可能与过敏性鼻炎(AR)中气道对过敏原的反应性增加有关。臭氧老化环境黑碳(O3BC)是大气颗粒物(PM)的一个重要组成成分,其对过敏性鼻炎的影响机制尚未完全阐明。

Laryngoscope:皮下与舌下免疫疗法在成人过敏性鼻炎中的治疗

过敏性鼻炎(AR)是一种以打喷嚏、流鼻涕和鼻腔阻塞为特征的疾病,常伴有眼睛发痒、鼻子发痒、鼻后滴液、咳嗽和疲劳等症状。据估计,AR的患病率高达42%,影响到美国大约5800万人。AR患者有着很大的经济

盘点:近期鼻炎的药物治疗进展

【1】Allergy:鼻内皮质激素治疗对2型先天淋巴细胞的影响研究

Eur Arch Otorhinolaryngol:Ectoin ®鼻炎喷雾剂与赛洛唑啉作为急性鼻炎治疗方案的比较

鼻窦炎是一种非常普遍的疾病,对患者的生活质量(QoL)有显著的负面影响,并造成社会经济负担。根据《欧洲鼻炎和鼻息肉意见书》(EPOS 2012),鼻窦炎定义为鼻子和副鼻窦的炎症,有两个或更多的症状,其

盘点:近期鼻部疾病研究进展(七)

鼻炎即鼻腔炎性疾病,是病毒、细菌、变应原、各种理化因子以及某些全身性疾病引起的鼻腔黏膜的炎症。鼻炎的主要病理改变是鼻腔黏膜充血、肿胀、渗出、增生、萎缩或坏死等。梅斯医学小编整理了近期鼻炎的研究进展,与